Mean platelet volume (MPV), measured using automated blood analysers, has been appraised as a potential biomarker in cardiovascular disease, diabetes mellitus, and cancer. The test, a useful tool in differentiation of thrombocytopenic states, has now been carried out for autoimmune disorders, but data are yet scarce. Controversial results have been obtained in systemic and organ-specific autoimmune disorders. Another test, the immature platelet fraction (IPF) reflects the amount of young, reticulated platelets. IPF is calculated by automated hematology analysis or flow cytometry, and it is usually high in patients with rapid platelet destruction. For both MPV and IPF, standardization of cutoff is a major need. In this review, we focus the current applicability of MPV and IPF as biomarkers in patients with autoimmune diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592196 | PMC |
| http://dx.doi.org/10.3389/fmed.2017.00146 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral GVHD post-cardiac xenograft valve replacement: a case report.
J Cardiothorac Surg
December 2024
Department of Anatomical Pathology, Pathology, King Faisal Specialist Hospital and Research Centre, Al-Rawdah Street, Jeddah, Saudi Arabia.
Background: Graft versus host disease (GVHD) is an autoimmune disease that affects the oral cavity as well as other parts of the body. Oral GVHD occurs in 45-83% of cases, and chronic GVHD observed in 30-50% of cases usually manifests as an oral presentation.
Case Presentation: In this case report, a 13 years-old girl was referred to the periodontics clinic from the pediatric dentistry clinics for proper diagnosis and management of the oral presentations observed after receiving a prosthetic valve replacement 2 years ago.
Identification of shared pathogenic signatures of multiple sclerosis and chronic obstructive pulmonary disease: an integrated transcriptomic analysis of blood specimens.
Mol Genet Genomics
December 2024
Department of Cell and Molecular Biology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran.
Patients with multiple sclerosis (MS) face a heightened risk of developing chronic obstructive pulmonary disease (COPD). Despite this widely reported association, the pathogenic contributors and processes that may favor the development of COPD in MS patients have yet to be identified. Recent studies have suggested peripheral blood leukocytes as a potential link between COPD and autoimmune disorders.
View Article and Find Full Text PDF[Subcutaneous Injection of Efgartigimod, a New Therapeutic Agent for Generalized Myasthenia Gravis].
Brain Nerve
January 2025
Department of Neurology, Graduate School of Medicine, Chiba University.
Patients with generalized myasthenia gravis (gMG) suffer from significant physical and social burdens. Although immunotherapies have been widely used for the treatment of gMG, some patients do not achieve or maintain remission. Recently, several molecular-targeting therapies of gMG, including the intravenous infusion of efgartigimod alfa (efgartigimod IV), a neonatal Fc receptor inhibitor, have been developed and are clinically used in Japan.
View Article and Find Full Text PDF[Response if the Three Mainstay Treatments for Chronic Inflammatory Demyelinating Polyradiculoneuropathy Are Ineffective or Insufficient].
Brain Nerve
January 2025
Department of Neurotherapeutics, Yamaguchi University School of Medicine.
The effectiveness of chronic inflammatory demyelinating polyneuropathy (CIDP) treatment is difficult to evaluate based on disease characteristics and treatment methods. The first basic concept of CIDP treatment is "to prevent undertreatment due to inadequate treatment and not overlook patients who can be saved." The second concept is "to prevent overtreatment by unnecessary treatment and discontinue excessive therapy for patients.
View Article and Find Full Text PDF[Treatment Strategies for Chronic Inflammatory Demyelinating Polyneuropathy].
Brain Nerve
January 2025
Department of Neurology, Dokkyo Medical University.
Three main treatments are available for management of chronic inflammatory demyelinating polyneuropathy (CIDP). Both induction and maintenance therapies should be considered for treatment of CIDP. Plasma exchange and intravenous immunoglobulin therapy are effective as induction treatments for CIDP, and corticosteroid administration, such as daily oral or pulse therapies, may be effective for both induction and maintenance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!